"" (translated)
За мен новината е историческа и намирам, че не е достатъчно отразена. На 19 август 2026 г. Moderna и Merck (MSD) обявиха резултатите от мащабно клинично изпитване във фаза 3: Персонализираната mRNA ваксина срещу меланом (intismeran / mRNA-4157) в комбинация с Keytruda значително намалява риска от връщане и разпространение на рака. Това е първата mRNA противоракова ваксина, която успешно преминава късна фаза на клинични изпитвания. В проучването участваха над 1100 пациенти с висок риск за меланом (стадий IIB–IV), при които туморът е бил напълно отстранен хирургично. Комбинацията ваксина + Keytruda значително удължава времето без рецидив (recurrence-free survival) и намалява риска от поява на далечни метастази в сравнение само с Keytruda. Ваксината е напълно персонализирана - създава се специално за всеки пациент въз основа на уникалните мутации на неговия тумор. Използва се същата mRNA технология, която познаваме от ваксините срещу COVID-19. Това не е просто пореден „пробив в лабораторията“. Това е реална стъпка към нова ера в онкологията. Резултатите вече се наричат „landmark“ (исторически) от водещи онколози. Компаниите планират да подадат документи за одобрение от регулаторите в близките месеци. Ако всичко върви добре, хиляди пациенти могат да се възползват още през 2027 г. Понякога истински революции идват тихо, но променят живота на хиляди хора. #mRNAvaccine #oncology #cancerresearch
The mRNA vaccine success vs melanoma in a Phase definitive 3 randomized trial today is on top of signs of success for personalized mRNA neoantigen vaccines vs pancreatic cancer, triple negative breast cancer, and non-small cell lung cancer https://t.co/cv4iXW11mw #mRNAvaccine #CancerResearch #Immunotherapy #Nospecificcountrycodesarementionedinthetweet.
I believe AI models could eventually design end-to-end pipelines for mRNA therapeutics in both cancer and autoimmune diseases. In personalized cancer vaccines, the pipeline could look like this: Tumor WES/RNA-seq → somatic mutation identification → mutant allele expression → #AIMedicine #mRNAtherapeutics #CancerResearch #Therearenospecificcountriesmentionedinthetweetprovided.Therefore #theresponseisempty.
Israeli scientists have generated novel remedies for cancer, Alzheimer’s and so many other diseases. Maybe we can cure this too, if we apply ourselves? #CancerResearch #Alzheimers #MedicalInnovation #IL
New @NatureMedicine paper: A pan-cancer foundation model predicts immunotherapy response and highlights the biology behind it https://t.co/hfVQc24r6w @harvardmed news: https://t.co/1w6u8cEYBK Roughly a quarter of patients with advanced cancer respond durably to immune #CancerResearch #Immunotherapy #HealthTech #Nospecificcountrycodesfound.
Prinzessin Kate und König Charles nahmen an einer emotionalen Veranstaltung im St. James’s Palace teil, um das 125-jährige Bestehen von „Cancer Research UK“ zu feiern, wo Kate in einem auffälligen roten Herzchen-Kleid auftrat und ihre eigene Krebsdiagnose von 2024 zum Anlass nahm, um den Kampf gegen die Krankheit zu unterstützen. #Krebscharity #PrinzessinKate #CancerResearchUK
Im besonderen Dress bei Krebs-Charity - Kates Termin geht ans Herz
Supported by over €20m from 🇨🇿 Recovery Plan @eu_next, this Centre brings together cancer research, prevention and care under one roof. Around 40% of cancer cases could be prevented. Investing in prevention & early detection gives people a stronger chance against the disease. #CancerResearch #PreventionMatters #EarlyDetection #CZ
Met with Isabel Rubio, President of @EuropeanCancer, which is advancing cancer research, treatment, care & policy. Through initiatives like the Life Science Strategy & #MissionCancer, the EU is fighting against youth cancer & funding multi-country clinical trials. https://t.co/q2IfcJo1DZ #CancerResearch #YouthCancer #EUHealth #EU
RT @ScienceFocusonX: A tiny bee just did what chemotherapy couldn't. Scientists in Australia discovered that honeybee venom can wipe out 1… #HoneybeeVenom #CancerResearch #ScienceNews #AU
RT @RuxandraTeslo: Mutations in KRAS are found in 90% of pancreatic cancers, one of the most fatal types of cancer. For decades, we could n… #PancreaticCancer #KRAS #CancerResearch #Nospecificcountrycodesarementionedinthetweet.
Napad na paradi ponosa v Berlinu: en mrtev, 16 ranjenih
R
U.S. cancer centers are rapidly trying to enroll patients in an early access program for daraxonrasib, a promising new pancreatic cancer drug from Revolution Medicines, following its FDA approval for expanded access after demonstrating a significant increase in survival rates in clinical trials. #PancreaticCancer #FDAApproval #CancerResearch #US #CA #NE
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
R
U.S. cancer centers are urgently enrolling patients in an early access program for Revolution Medicines' promising pancreatic cancer drug, daraxonrasib, following its recent FDA approval for expanded access, which comes after clinical trials showed it can double survival rates in advanced cases of the disease. #CancerResearch #FDAApproval #PancreaticCancer #US
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
R
U.S. cancer centers are urgently enrolling patients in an expanded access program for the promising pancreatic cancer drug daraxonrasib, which recently showed in clinical trials to significantly extend survival, while they await expected FDA approval amidst a surge of patient requests. #CancerResearch #FDAApproval #PancreaticCancer #US
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
R
U.S. cancer centers are rapidly trying to enroll patients in an early access program for Revolution Medicines' promising pancreatic cancer drug, daraxonrasib, following its FDA-approved expanded access due to its significant survival benefits demonstrated in clinical trials, amidst a surge of patient requests and logistical challenges in managing the program. #CancerResearch #FDAApproval #PancreaticCancer #US
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
R
U.S. cancer centers are rapidly enrolling patients in an early access program for daraxonrasib, a promising pancreatic cancer drug from Revolution Medicines, after the FDA approved the program following positive trial results that showed the drug doubled patient survival, while oncologists face logistical challenges in managing patient requests and navigating the approval process. #CancerResearch #FDAApproval #PancreaticCancer #US
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
The article by Gina Kolata and Rebecca Robbins highlights the potential breakthrough in pancreatic cancer treatment with daraxonrasib, an experimental drug that has shown to significantly prolong patients' lives by targeting the previously deemed "undruggable" KRAS protein, signaling a major advancement in cancer therapy after decades of challenges and failures. #CancerResearch #PancreaticCancer #InnovativeMedicine #US #CA
El cáncer de páncreas tiene un gran avance
In an article by Gina Kolata and Rebecca Robbins, 27 scientists, doctors, and clinical trial participants discuss the groundbreaking potential of daraxonrasib, a drug nearing FDA approval that significantly extends the lives of pancreatic cancer patients by targeting the KRAS protein, marking a significant advancement in cancer treatment after decades of failed experimental therapies. #CancerResearch #PancreaticCancer #ClinicalTrials #USA #MIT #Harvard #NC #MI #CA #NY #EU
El cáncer de páncreas tiene un gran avance
The article discusses the significant breakthrough in pancreatic cancer treatment with daraxonrasib, a drug that has shown promise in extending the lives of patients, marking a potential turning point after decades of failures and challenging the long-held belief that targeting the KRAS protein was impossible. #PancreaticCancer #CancerResearch #MedicalBreakthrough #US #CA
El cáncer de páncreas tiene un gran avance
